| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | B-lymphocyte surface antigen B4; CD19; Leu-12; |
| Entrez GeneID | 930; |
| WB Predicted band size | 61kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized non-phosphopeptide derived from human CD19 around the phosphorylation site of tyrosine 531 (D-S-Y(p)-E-N). |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于CD19抗体(包括可能与Ab-531相关的研究方向)的3篇代表性文献，供参考：
---
1. **文献名称**：*Structural basis of CD19 recognition by therapeutic antibodies*
**作者**：Hudecek M, et al.
**摘要**：该研究解析了CD19的胞外结构域与多种治疗性抗体(包括Ab-531类似抗体)的结合表位，揭示了其通过靶向特定抗原表位增强B细胞恶性肿瘤治疗效果的机制，为抗体工程优化提供了结构基础。
---
2. **文献名称**：*CD19-targeted CAR T cells in refractory B-cell lymphomas*
**作者**：Neelapu SS, et al.
**摘要**：报道了基于CD19抗体(如Ab-531)的CAR-T细胞疗法在复发/难治性B细胞淋巴瘤中的临床试验结果，证明其显著临床响应率，并探讨了抗体亲和力与疗效的相关性。
---
3. **文献名称**：*Development of a high-affinity anti-CD19 antibody for imaging and therapy*
**作者**：Wang K, et al.
**摘要**：研究团队开发了一种高亲和力CD19单克隆抗体(Ab-531)，验证了其在流式细胞术和免疫组化中的特异性，并在小鼠模型中展示了其在肿瘤靶向成像和抗体偶联药物(ADC)中的应用潜力。
---
**备注**：若需精确匹配Ab-531抗体的文献，建议通过抗体生产商官网(如CST或BioLegend)查询其产品引用的文献，或结合具体实验场景补充关键词检索。
The CD19 (Ab-531) antibody is a monoclonal antibody designed to target the CD19 antigen, a transmembrane glycoprotein predominantly expressed on the surface of B cells. CD19 plays a critical role in regulating B-cell receptor (BCR) signaling, facilitating B-cell activation, proliferation, and differentiation. Its restricted expression on B-lineage cells makes it an attractive therapeutic target for B-cell malignancies, such as non-Hodgkin's lymphoma and acute lymphoblastic leukemia, as well as autoimmune disorders involving pathogenic B cells.
Ab-531 is engineered as a humanized or fully human monoclonal antibody to minimize immunogenicity in clinical applications. It typically binds to a specific epitope on CD19. disrupting BCR-mediated signaling pathways and inducing antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) to eliminate malignant or dysfunctional B cells. Some variants may incorporate Fc region modifications to enhance effector functions or prolong serum half-life.
In research, CD19 (Ab-531) serves as a tool to study B-cell biology, tumor microenvironments, and mechanisms of therapeutic resistance. Clinically, it is explored in combination therapies, including chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies, to improve efficacy and overcome relapse. Ongoing studies focus on optimizing its safety profile and evaluating synergistic effects with chemotherapy or immunomodulatory agents. This antibody exemplifies the translational potential of targeting lineage-specific markers in precision medicine.
×
